TGF-β/Smad Signaling


The TGF-β family is generally classified into two sub-families, TGF-β ligands, and bone morphogenic protein (BMP) ligands. In canonical signaling, receptor activation lead to phosphorylation of a group of transcription factors called Smads. TGF-β ligands bind to type II receptors (TGF-β II) which recruit and phosphorylate type I receptor (TGF-β I) on serine/threonine residues. The TGF-β I then recruits and phosphorylates a receptor regulated Smad (R-Smad). The R-Smad binds to the common Smad (Co-Smad) and forms a heterodimeric complex. This complex then translocates into the cell nucleus where it binds with nuclear co-factors to regulate the transcription of various target genes. Dysregulation of TGF-β/Smad signaling pathway is associated with a number of pathological conditions including fibrosis, cancer, immunodeficiency, diabetes and cardiovascular diseases etc.
-
B2286 K02288Target: ALKSummary: ALK inhibitor -
B3379 Verbascoside2 CitationSummary: PKC/NF-κB inhibitor -
B1176 Y-39983 dihydrochlorideSummary: ROCK family inhibitor -
B1011 Bafetinib (INNO-406)2 CitationSummary: Bcr-Abl/Lyn tyrosine kinase inhibitor -
B1404 DCC-2036 (Rebastinib)Target: FLT3|Bcr-Abl|Tie-2|KDRSummary: Bcr-Abl inhibitor -
B1294 SR-3677Target: ROCKSummary: Rho Kinase (ROCK-II) inhibitor -
B2289 SB505124Summary: ALK4/ALK5/ALK7 inhibitor -
B1287 Ro 31-8220Target: PKCSummary: pan-PKC inhibitor -
B7931 ButaprostSummary: Structural analog of PGE2, a selective agonist for the EP2 receptor subtype -
C4877 1,2-Distearoyl-sn-glycerol

